LONDON, UK / ACCESSWIRE / June 1, 2017 / Active Wall St. blog coverage looks at the headline from Array BioPharma Inc. (NASDAQ: ARRY) and Bristol-Myers Squibb Co. (NYSE: BMY) as both companies announced on May 30, 2017, that they have entered into a clinical research to investigate the safety, tolerability, and efficacy of Array's investigational MEK inhibitor, binimetinib, along with Myers Squib's Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

Today, AWS is promoting its blog coverage on ARRY and BMY. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

The Announcements

Array BioPharma believes that this new collaboration will enable the study of combinations of targeted therapies, such as binimetinib, with immuno-oncology agents, such as Opdivo and Yervoy which could offer important scientific advances for patients fighting cancer. The Phase-1/2 study is expected to designate recommended dose regimens for further study and explore the preliminary anti-tumor activity of combining binimetinib with Opdivo, and bin imatinib in combination with the Opdivo + Yerboy regimen.

The results from this study, which is expected to begin in the second half of 2017, will be used to determine optimal approaches to accelerate clinical development of these combinations. Under the agreement, Array will act as a sponsor and both the Companies will jointly support the study.

Advaxis-Bristol-Myers Squibb Agreement

On May 30, 2017, Bristol-Myers and Advaxis launched a clinical development program to evaluate ADXS-DUAL, an investigational immunotherapy targeting HPV-associated cancers, and Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo (nivolumab). This study is expected to start this year and will help evaluate the combination regimen in women with persistent, recurrent or metastatic carcinoma of the cervix who have failed at least one prior line of systemic chemotherapy.

Under terms of the Agreement, each Company has agreed to bear their own internal costs and deliver immunotherapy agents. Advaxis has agreed to sponsor the study and pay third-party costs.

Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body's own immune system and helps restore anti-tumor immune response. Opdivo has turned out to be an important treatment solution across multiple cancers as it harnesses the body's own immune system to fight cancer. In October 2015, the Opdivo and Yervoy combination regimen was the first Immuno-Oncology combination to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 50 countries.

The global development program for Opdivo is based on Bristol-Myers Squibb's scientific expertise in the field of Immuno-Oncology and includes a wide array of clinical trials across different phases, including Phase-3, in a variety of tumor types. The Opdivo clinical development program has enrolled more than 25,000 patients, to date, and the trials have contributed to gaining a deeper insight of the potential role of biomarkers in patient care.

Recently, on April 28, 2017, Bristol-Myers Squibb announced that the European Commission (EC) approved Opdivo as the monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy. As a matter of fact, Opdivo is the first and only Immuno-Oncology (I-O) treatment that demonstrated a significant improvement in Phase-3 trial results, in overall survival for the patients.

Stock Performance

At the close of trading session on Wednesday, May 31, 2017, Array BioPharma's stock price dropped 3.56% to end the day at $7.58. A total volume of 5.63 million shares were exchanged during the session, which was above the 3-month average volume of 4.05 million shares. The Company's share price has skyrocketed 101.06% in the past twelve months. The stock currently has a market cap of $1.31 billion.

Bristol-Myers Squibb's share price finished yesterday's trading session at $53.95, slightly up 0.04%. A total volume of 8.15 million shares exchanged hands. The stock is trading at a PE ratio of 18.71 and has a dividend yield of 2.89%. At Wednesday's closing price, the stock's net capitalization stands at $89.57 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street